Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Athira Pharma Inc (ATHA)

Athira Pharma Inc (ATHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,578
  • Shares Outstanding, K 3,944
  • Annual Sales, $ 0 K
  • Annual Income, $ -96,940 K
  • EBIT $ -39 M
  • EBITDA $ -39 M
  • 60-Month Beta 2.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.57

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 68.44%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,003.46% on 12/13/24
  • IV Low 0.00% on 12/02/25
  • Expected Move (DTE 40) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 95
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 283
  • Open Int (30-Day) 4,995
  • Expected Range 4.04 to 4.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -3.90
  • Growth Rate Est. (year over year) +25,715.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.71 +6.47%
on 11/07/25
5.00 -21.00%
on 11/17/25
-0.24 (-5.73%)
since 11/05/25
3-Month
3.52 +12.06%
on 09/11/25
5.00 -21.00%
on 11/17/25
+0.05 (+1.20%)
since 09/05/25
52-Week
2.20 +79.95%
on 04/08/25
6.68 -40.86%
on 12/09/24
-2.30 (-36.80%)
since 12/05/24

Most Recent Stories

More News
Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update

Continuing to explore strategic alternatives focusing on maximizing stockholder value   Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable...

ATHA : 3.95 (+1.41%)
Athira Pharma Announces Reverse Stock Split

BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules...

ATHA : 3.95 (+1.41%)
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025

BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...

ATHA : 3.95 (+1.41%)
Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

BOTHELL, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...

ATHA : 3.95 (+1.41%)
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

ATHA : 3.95 (+1.41%)
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

ATHA : 3.95 (+1.41%)
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

ATHA : 3.95 (+1.41%)
Athira Pharma Presents Promising Preclinical Data on ATH-1105 for Neuroprotection in ALS at International Symposium

Athira Pharma presented preclinical data on ATH-1105's neuroprotective effects in ALS at an international symposium in Montreal.Quiver AI SummaryAthira Pharma, Inc., a clinical-stage biopharmaceutical...

ATHA : 3.95 (+1.41%)
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND

ATHA : 3.95 (+1.41%)
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

ATHA : 3.95 (+1.41%)

Business Summary

Athira Pharma Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira Pharma Inc. is based in SEATTLE.

See More

Key Turning Points

3rd Resistance Point 4.13
2nd Resistance Point 4.04
1st Resistance Point 4.00
Last Price 3.95
1st Support Level 3.87
2nd Support Level 3.78
3rd Support Level 3.74

See More

52-Week High 6.68
Fibonacci 61.8% 4.97
Fibonacci 50% 4.44
Last Price 3.95
Fibonacci 38.2% 3.91
52-Week Low 2.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar